The first patient in the Chinese portion of the Denali phase 3 clinical trial, investigating NCX 470 in patients with open-angle glaucoma or ocular hypertension, has been screened, according to a press release from Nicox.
Denali is evaluating the efficacy of NCX 470 ophthalmic solution 0.1% compared with latanoprost ophthalmic solution 0.005% to lower IOP in patients with open-angle glaucoma or ocular hypertension. The study will enroll about 670 patients in the U.S. and China, with U.S. patient enrollment ongoing since November 2020.
“NCX 470 is one of the key (Read more...)